Atlas Trials

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Clinical trial NCT05470504 · RECRUITING

Trial details

NCT number
NCT05470504
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Insulin Receptor MutationPartial Lipodystrophy
Start date
2023-01-23
Primary completion
2028-01-30
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.